Trials Sponsors Conditions Drugs Pricing

Conditions

Type 2 Diabetes

Outcome Measures

Primary Outcomes (2)

Copeptin Concentration (pg/ml)
Copeptin serum Level
3 month
NT-proBNP Concentration (pg/ml)
NT-proBNP serum Level
3 Months

Secondary Outcomes (1)

Fasting blood glucose (mg/dl)
3 month

Study Arms (2)

Vildagliptin

EXPERIMENTAL

Group I (N=35) are patients who the endocrinologist prescribed them Vildagliptin 50mg /tab plus their Metformin 500mg /tab once daily for 12 weeks to control their blood sugar level.

Drug: Vildagliptin 50 MG

Glimepiride

ACTIVE COMPARATOR

Group II (N=35) are patients who the endocrinologist prescribed them Glimepiride 3mg / tab plus Metformin 500mg /tab once daily for 12 weeks.

Drug: Glimepiride 3 Mg Oral Tablet

Interventions

Vildagliptin 50 MGDrug

vildagliptin plus their metformin.

Also known as: Vildagliptin

Vildagliptin

Glimepiride 3 Mg Oral TabletDrug

glimepiride plus their metformin

Also known as: Amaryl

Eligibility Criteria

Age35 Years - 80 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

70 uncontrolled adult patients with Type II-diabetes mellitus

You may not qualify if:

Sponsors & Collaborators

Damanhour University
Otherlead

Study Sites (1)

Damanhour Teaching Hospital, General Organization for Teaching Hospitals and Institutes.

Damanhūr, Elbehairah, 31527, Egypt

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

VildagliptinglimepirideTablets

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

NitrilesOrganic ChemicalsPyrrolidinesHeterocyclic Compounds, 1-Ring

Study Officials

Rehab H Werida, Ass Prof.
Damanhour University
STUDY CHAIR

Enrollment

70 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, INVESTIGATOR
Masking Details: Double Blind
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Associate Professor

Study Record Dates

First Submitted

September 29, 2023

First Posted

October 5, 2023

Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (2)

Vildagliptin

Glimepiride

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Study Arms (2)

Vildagliptin

Glimepiride

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations